NOVALANT (Nova Pharmaceuticals Australasia Pty Ltd)
Product name
NOVALANT
Date registered
Evaluation commenced
Decision date
Approval time
109 (255 working days)
Active ingredients
ticagrelor
Registration type
New generic medicine
Indication
NOVALANT, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [UA], non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).